• 繁

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Is Sionna Therapeutics (SION) Undervalued Or Already Priced In As Index Changes Draw Focus?

    Simply Wall St·07/05/2026 00:30:57
    語音播報

    Sionna Therapeutics (SION) is in focus after being removed from several Russell indexes, following a US$5.27 million stock sale by director Peter A. Thompson under a pre-arranged Rule 10b5-1 trading plan.

    See our latest analysis for Sionna Therapeutics.

    The share price of Sionna Therapeutics has moved to US$43.99, with a 1-day share price return of 5.64% and a 30-day share price return of 16.44%. The 1-year total shareholder return of 107.60% points to strong longer term momentum despite recent index removals and director selling.

    If Sionna Therapeutics has your attention, it can also be useful to see how other healthcare AI focused stocks are trading right now, starting with 40 healthcare AI stocks.

    With Sionna Therapeutics trading at US$43.99 and sitting about 17% below the average analyst price target of US$51.60, the key question is whether this reflects an undervalued CF pipeline or whether the market is already pricing in future growth.

    Preferred Price-to-Book Multiple of 6.9x: Is It Justified?

    Sionna Therapeutics trades on a P/B of 6.9x, which puts a clear premium on the stock compared with the wider US Biotechs industry and raises questions about what the market is paying for today.

    The price to book ratio compares the company’s market value to its net assets, which is often a reference point for early stage biopharmaceutical stocks that are still loss making and have little or no revenue. With Sionna Therapeutics reporting a loss of $85.565m and revenue of $0, investors are effectively valuing the pipeline, intellectual property and future potential rather than current earnings power.

    Compared with the US Biotechs industry average P/B of 2.8x, Sionna Therapeutics trades at more than double that level, indicating that the stock is expensive on this measure. At the same time, its 6.9x P/B sits well below the 34.7x peer average highlighted in the data, which shows that even within a highly valued peer set there is a wide dispersion in how different companies are priced.

    See what the numbers say about this price — find out in our valuation breakdown.

    Result: Price-to-book of 6.9x (ABOUT RIGHT)

    However, Sionna Therapeutics still carries key risks, including its US$85.565m loss alongside zero revenue and the ever present uncertainty around clinical and regulatory outcomes.

    Find out about the key risks to this Sionna Therapeutics narrative.

    Next Steps

    The mixed signals around Sionna Therapeutics make this a stock that rewards closer inspection, so take a moment to review both sides of the story and weigh up the 1 key reward and 3 important warning signs flagged in the 1 key reward and 3 important warning signs.

    Looking for more investment ideas beyond Sionna Therapeutics?

    If Sionna Therapeutics has sharpened your focus, it is worth broadening your watchlist with other potential opportunities that fit different risk and income profiles.

    Use the Simply Wall St screener to quickly spot stocks that match your style, so you are not relying on a single story or sector for ideas.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.